论文部分内容阅读
目的:观察蒲地蓝消炎口服液治疗小儿风热咳嗽的临床疗效。方法:纳入248例风热咳嗽患儿,随机分成治疗组和对照组,治疗组给予蒲地蓝消炎口服液进行治疗,对照组采用西医常规治疗方法,口服利巴韦林片治疗。分析比较2组的临床治疗效果、症状体征改善情况、治疗依从性情况及不良反应发生情况。结果:2组愈显率、总有效率比较,差异均有统计学意义(P<0.01)。治疗后,治疗组咳嗽、咯痰、体温、恶寒、鼻塞、流涕、咽红肿等症状体征评分均低于对照组,差异均有统计学意义(P<0.05)。依从性优良率治疗组为98.4%,对照组为88.3%,2组比较,差异有统计学意义(P<0.01)。不良反应总发生率治疗组为2.3%,对照组为18.3%,2组比较,差异有统计学意义(P<0.01)。结论:采用蒲地蓝消炎口服液治疗小儿风热咳嗽,能够显著改善患儿的临床症状体征,疗效显著,安全可靠,价格低廉,值得临床推广应用。
Objective: To observe the clinical efficacy of Po Di Lan anti-inflammatory oral solution in children with wind-heat cough. Methods: A total of 248 children with wind-heat cough were enrolled and randomly divided into treatment group and control group. The treatment group was treated with Pudilan anti-inflammatory oral liquid. The control group was treated with conventional western medicine and oral ribavirin tablets. Analysis of two groups of clinical treatment, the improvement of symptoms and signs, treatment compliance and adverse reactions. Results: The cure rate and total effective rate of two groups were statistically significant (P <0.01). After treatment, the cough, expectoration, body temperature, aversion to cold, nasal congestion, runny nose, swollen swollen and other symptoms and signs were lower in the treatment group than in the control group, the difference was statistically significant (P <0.05). The rate of compliance was 98.4% in the treatment group and 88.3% in the control group. There was significant difference between the two groups (P <0.01). The total incidence of adverse reactions in the treatment group was 2.3%, 18.3% in the control group, the difference between the two groups was statistically significant (P <0.01). Conclusion: Puda Di anti-inflammatory oral solution in children with wind-heat cough, can significantly improve children’s clinical signs, significant effect, safe, reliable, low price, worthy of clinical promotion and application.